BMS extends deal with Samsung as its pipeline percolates with more biologics

Eric Palmer With a host of biologic products in its pipeline, Bristol-Myers Squibb sees the need for more capacity for making large-molecule drugs and has decided to build on a relationship ...

GSK and Novartis reshape EU biotech, Celgene and Hyperion in Euro deals, U.K. cell therapy grows

Nick Paul Taylor In the latest edition of our weekly EuroBiotech Report, the card shuffling at GlaxoSmithKline and Novartis is raising questions about the future of several companies. ...

Allergan poison pill presages a battle against Valeant’s $47B takeover

Carly Helfand Valeant may think Allergan is a great buyout fit, as evidenced by the $ 47 billion bid it made for the California company Tuesday. But Allergan may feel differently–at ...

Novartis, GSK deal puts the spotlight on a narrowing R&D focus

John Carroll The big trend in Big Pharma R&D has been to cut back significantly in key areas where they felt they faced extraordinarily high risks–a particular problem in ...

An international biotech tackles CRISPR gene editing tech with $25M bankroll

John Carroll A hybrid international biotech upstart with deep U.S. academic roots, a company base in Basel and a plan to grow its research operations in London has landed a $ 25 million ...

Biogen revenue leaps 50% on blockbuster-level Tecfidera sales

Tracy Staton Launched last April, Tecfidera racked up more than a half-billion dollars in sales for the first quarter of this year. That puts its cumulative total at $ 1.38 billion–well ...

Should Amgen join the biopharma breakup party? Analyst says maybe

Tracy Staton Now that the Big Pharma breakup craze has moved down the drugmaker food chain to Baxter International, should Big Biotech jump on the trend? Maybe one of that group, an ...

GSK’s R&D staff hit with trade rumors spurred by Novartis’ cancer pact

John Carroll GlaxoSmithKline hasn't spelled out exactly how its big deal with Novartis will impact individual workers. But the rumor mill has it that more than 100 investigators ...

VC groups put up $165M for a trifecta of biotech rounds

John Carroll A Detroit-based biotech has landed a $ 59.5 million round to continue its work on a nucleic acid-based DNAi cancer therapy now in a mid-stage trial. ProNAi Therapeutics ...

Gilead’s Sovaldi turns in outsize Q1 sales

Eric Palmer Powered by sales that averaged more than $ 25 million a day for brand-new hep C drug Sovaldi, Gilead Sciences beat all expectations, with quarterly sales that nearly doubled ...

Epizyme jumps on $4M payday

John Carroll Shares of Cambridge, MA-based Epizyme jumped 10% this morning after the company announced that it had won a $ 4 million payment from GSK after hitting the third of the ...

Valeant touts quick cost cuts in $45B hostile bid for Allergan

Carly Helfand As The Wall Street Journal reports, the Irvine, CA-based Allergan is the latest apple of deal-happy Valeant's eye. And allied with activist investor Bill Ackman–who ...
Page 3 of 512345
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS